Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023
Due Dates: October 11, 2023
Open Date: Earliest Submission Date: September 11, 2023
The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.
More information here
Peer Reviewed Medical Research Program (PRMRP)
The Peer Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service Members, Veterans, retirees, and their family members.
FY2023 Funding Mechanisms have been announced! The Congressionally Directed Topic Areas include:
- Clinical Trial Award (CTA)
- Discovery Award (DA)
- Focused Program Award (FPA)
- Investigator-Initiated Research Award (IIRA)
- Lifestyle and Behavioral Health Interventions Research Award (LBIRA)
- Technology/Therapeutic Development Award (TTDA)
Letter of Intent is Due: April 19th, 2023
Full Applications are Due: May 31st, 2023
Learn more about this opportunity at https://cdmrp.health.mil/funding/prmrp
Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission
Open Date (Earliest Submission Date): February 05, 2023
Expiration Date: January 08, 2026
The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.
For more information click here
Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP), due September 07, 2022
Open Date (Earliest Submission Date): September 07, 2022
Expiration Date: May 08, 2025
The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.
This Notice also encourages applications to develop once-a-month SR/LA strategies for treatment of latent TB and hepatitis B
Biomarker Signatures of TB Infection in Young Children With and Without HIV (R01 Clinical Trial Not Allowed), due 06/08/2022
Open Date (Earliest Submission Date): May 08, 2022
Expiration Date: June 09, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to advance research to discover and validate novel biomarkers of Tuberculosis (TB) infection and subsequent risk of progression to TB disease in young children with and without HIV.
Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed), due 07/08/2022
Open Date (Earliest Submission Date): June 08, 2022
Expiration Date: July 09, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to support the development of new diagnostic technologies for tuberculosis (TB) drug susceptibility testing (DST), including point of care (POC) DST and companion diagnostics for new TB drugs.
NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis
Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
Application open date: November 08, 2021
Expiration Date: December 09, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.
Click here for more information about this funding opportunity!
Advancing Vaccine Adjuvant Research for Tuberculosis (TB)
Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"
Contract Opportunity Type: Solicitation
The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five -year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five  years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT
Postdoctoral Fellowship opportunity in Global HIV & TB Research
Post-Doctoral Research Fellowships for Global HIV and TB Public Health Programs
The mission of this fellowship program is to recruit, mentor, and train scientist-practitioners to conduct global HIV and TB research and to develop the translational and applied skills necessary to implement and support high-quality HIV and TB public health programs in global settings. The goal of this fellowship is to attract and support recent recipients of doctoral degrees to understand the underpinnings of interventional epidemiology and to prepare them for a career operating at the intersection of science and practice in global public health. The selected candidates will be in the Division of Global HIV & TB (DGHT) at the Centers for Disease Control and Prevention (CDC), headquartered in Atlanta, GA. The DGHT Office of the Director (DGHT OD) is the lead for the program. Fellows will also be paired with DGHT’s programmatic or data branches on various projects throughout their fellowship.
The deadline to apply to this fellowship is June 30, 2021. The fellowship is scheduled to begin Fall 2021, subject to availability of funds.
Click here for more information about this fellowship!
Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB)
Application Due Date: Pending
The goals of this planned award are:
1) to stimulate the development and implementation of new tools and approaches to accelerate the prevention, detection and management of tuberculosis in adults and children and
2) strengthen local capacity to design, implement, disseminate and use findings from TB research.
Anticipated Award Date: 9/30/2021